...
首页> 外文期刊>Diagnostic pathology >Peritumoral/vascular expression of PSMA as a diagnostic marker in hepatic lesions
【24h】

Peritumoral/vascular expression of PSMA as a diagnostic marker in hepatic lesions

机译:PSMA的腹膜/血管表达作为肝病变中的诊断标志物

获取原文
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND:The differential diagnosis between primary cholangiocarcinoma and metastatic pancreatobiliary adenocarcinoma is histologically challenging due to lack of distinct morphological features and reliable molecular markers. Prostate-specific membrane antigen (PSMA) is expressed in prostate epithelium and upregulated on the surface of prostatic adenocarcinoma cells. Studies have shown PSMA enzymatic activity is involved in malignancy-driven neoangiogenesis in the endothelium of tumor-associated neovasculature in breast, lung, thyroid, hepatocellular carcinoma (HCC) and urothelial cancer. Recently, PSMA-targeted imaging technology (PSMA PET-CT) detected the presence of PSMA in primary cholangiocarcinoma. However histological correlation with PSMA expression other mass lesions in the liver has not yet been studied.METHODS:72 cases of liver mass resection were collected at a tertiary hospital from 2011 to 2019. Immunohistochemical stains for PSMA and CD34 were performed. The expression of PSMA in tumor cells and associated neovascular endothelium were analyzed separately and the locations of vascular structures were confirmed by CD34 expression.RESULTS:Among 72 cases, 28 cases (22/72, 38.9%) showed PSMA peritumoral/vascular expression only, 3 cases (3/72, 4.2%) showed tumor cell expression only, and 2 cases (2/72, 2.8%) showed both tumor cell and peritumoral/vascular expression. The remainder (39/72, 54.2%) showed no expression. Particularly, most of primary cholangiocarcinoma showed PSMA vascular expression (13/15, 86.7%), while none of the 18 cases of metastatic pancreatobiliary adenocarcinoma were positive for PSMA (0/18, 0%) (p??0.01). Outside of pancreatobiliary adenocarcinoma, none of the metastatic tumors, including colon and lung cancers, expressed PSMA. In 8 cases of metastatic prostate carcinoma, 3 showed PSMA expressions in tumor cells only (3/8, 37.5%) and 2 expressed PMSA in both tumor cells and neovasculature (2/8, 25.0%). Out of 22 HCC cases, 15 (15/22, 68.2%) were positive for PSMA in tumor vasculature. None of the 5 hepatic adenoma expressed PSMA (0/5, 0%).CONCLUSION:Significantly enhanced tumor-associated neovascular PSMA expression was identified in primary cholangiocarcinoma, compared to metastatic pancreatobiliary adenocarcinoma. Our findings potentially provide a sensitive marker in differential diagnosis between otherwise morphologically indistinguishable cases.
机译:背景:由于缺乏不同的形态特征和可靠的分子标记,原代胆管癌和转移性胰腺腺癌之间的差异诊断是组织学上挑战性的。前列腺特异性膜抗原(PSMA)在前列腺上皮中表达,并在前列腺腺癌细胞的表面上上调。研究表明,PSMA酶活性涉及乳腺癌,肺癌,甲状腺,肝细胞癌(HCC)和尿路上皮癌的肿瘤相关新血管系统内皮的恶性肿瘤的新谐振发生。最近,PSMA靶向成像技术(PSMA PET-CT)在原代胆管癌中检测了PSMA的存在。然而,与PSMA表达的组织学相关性尚未研究肝脏中的其他质量病变。从2011到2019年,在第三次医院收集了72例肝脏肿块切除。进行PSMA和CD34的免疫组化染色。分别对肿瘤细胞和相关新生血管内皮进行PSMA的表达,并通过CD34表达证实了血管结构的位置。结果:在72例中,28例(22/72,38.9%)仅显示PSMA Peritumoral /血管表达, 3例(3/72,4.2%)显示肿瘤细胞表达仅表达,2例(2/72,2.8%)显示肿瘤细胞和扰动/血管表达。其余部分(39/72,54.2%)显示没有表达。特别是,大多数原代胆管癌显示PSMA血管表达(13/15,86.7%),而PSMA(0/18,0%)的18例转移性胰腺腺癌呈阳性阳性(p≤0.01)。外面的胰腺腺癌外,没有转移性肿瘤,包括结肠癌和肺癌,表达PSMA。在8例转移性前列腺癌中,3例在肿瘤细胞(3/8,37.5%)和2种表达的PMSA中显示出在肿瘤细胞和新生动物(2/8,25.0%)中的PSMA表达。在22例HCC病例中,15例(15/22,68.2%)在肿瘤脉管系统中为PSMA呈阳性。 5个肝腺瘤表达PSMA(0/5,0%)。结论:与转移性胰腺腺癌相比,在原代胆管癌中鉴定出显着增强的肿瘤相关的新血管PSMA表达。我们的发现可能在不同形态学难以区分的情况下在鉴别诊断中提供敏感标记。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号